Tenax Therapeutics (NASDAQ:TENX) Issues Quarterly Earnings Results, Beats Expectations By $0.34 EPS

Tenax Therapeutics (NASDAQ:TENX) posted its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.34, Zacks reports.

Tenax Therapeutics Stock Up 1.0 %

Tenax Therapeutics stock opened at $6.26 on Wednesday. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $7.89. The firm’s fifty day moving average is $6.44 and its 200 day moving average is $5.39.

Wall Street Analysts Forecast Growth

Several analysts recently commented on TENX shares. StockNews.com began coverage on Tenax Therapeutics in a report on Friday, March 21st. They issued a “sell” rating for the company. William Blair reaffirmed an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. Finally, Leerink Partners set a $20.00 price objective on shares of Tenax Therapeutics in a report on Monday, March 10th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Tenax Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $18.00.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.